Long-term Angiogenesis Efficacy Using a Heparin-Conjugated Fibrin (HCF) Delivery System with HBM-MSCs
International Journal of Stem Cells
; : 23-30, 2012.
Article
em En
| WPRIM
| ID: wpr-25525
Biblioteca responsável:
WPRO
ABSTRACT
BACKGROUND AND OBJECTIVES: Heparin-conjugated fibrin (HCF) is suitable for the release and localization of bFGF. We analyzed the effects of a bFGF delivery system using HCF with human bone marrow-derived mesenchymal stem cells (HBM- MSCs) in a dog ischemic limb model. METHODS AND RESULTS: Animals were divided into HBM-MSCs, HBM-MSCs+HCF, bFGF-HCF, and HBM-MSCs+bFGF-HCF groups. A total of 1x10(7) HBM-MSCs were injected per animal, and the amount of bFGF was 1 mg per dog. Ischemic muscles were harvested at eight weeks and six months after injection of cells. The HBM-MSCs+bFGF-HCF group exhibited decreased proportions of capillaries and arterioles six months after transplantation. However, there were more cells positive for the angiogenic factors, VEGF and PDGF, in the eight-week specimens compared with those harvested six months after transplantation. CONCLUSIONS: Our results demonstrated that a single injection of HBM-MSCs did not have significant long-term angiogenic effects; however, a bFGF delivery system using HCF exerted prolonged angiogenic effects when combined with HBM-MSCs.
Palavras-chave
Texto completo:
1
Base de dados:
WPRIM
Assunto principal:
Arteríolas
/
Doenças Vasculares
/
Capilares
/
Fibrina
/
Transplantes
/
Fator A de Crescimento do Endotélio Vascular
/
Indutores da Angiogênese
/
Extremidades
/
Células-Tronco Mesenquimais
/
Isquemia
Tipo de estudo:
Prognostic_studies
Limite:
Animals
/
Humans
Idioma:
En
Revista:
International Journal of Stem Cells
Ano de publicação:
2012
Tipo de documento:
Article